<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35477319</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1744-8409</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Expert review of clinical immunology</Title>
          <ISOAbbreviation>Expert Rev Clin Immunol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Emerging therapies for ulcerative colitis.</ArticleTitle>
        <Pagination>
          <StartPage>1</StartPage>
          <EndPage>12</EndPage>
          <MedlinePgn>1-12</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/1744666X.2022.2069562</ELocationID>
        <Abstract>
          <AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Despite advances in the medical management of ulcerative colitis (UC), a subgroup of patients does not respond to currently available therapies. A number of novel drugs are in late stages of clinical development or have recently received regulatory approval for UC.</AbstractText>
          <AbstractText Label="AREAS COVERED" NlmCategory="UNASSIGNED">This review focuses on three drug classes that have recently been approved or are awaiting approval for UC: antibodies against interleukin (IL)-23, sphingosine-1-phosphate receptor (S1PR) modulators, and selective inhibitors of Janus kinases (JAK). We provide an overview of their mechanism of action and summarize available evidence for their efficacy and safety. Finally, we discuss expected future challenges in UC management.</AbstractText>
          <AbstractText Label="EXPERT OPINION" NlmCategory="UNASSIGNED">The evaluated drugs have demonstrated efficacy with an acceptable safety profile. IL-23 antagonists appear to be safest with very few (serious) adverse events, while the use of S1PR modulators or JAK inhibitors has been associated with infectious and cardiovascular/thromboembolic events, albeit in low numbers. Although advances in drug development are promising, there is an urgent need for (validated) biomarkers to guide rational treatment selection. The scarcity of head-to-head trials also complicates comparisons between available drugs. Breaking the therapeutic ceiling of efficacy in UC will require marked advances in management extending well beyond drug development.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Hanzel</LastName>
            <ForeName>Jurij</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0003-3158-8014</Identifier>
            <AffiliationInfo>
              <Affiliation>Faculty of Medicine, University of Ljubljana, Department of Gastroenterology, University Medical Centre Ljubljana, Ljubljana, Slovenia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hulshoff</LastName>
            <ForeName>Melanie S</ForeName>
            <Initials>MS</Initials>
            <Identifier Source="ORCID">0000-0002-1792-2533</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, Amsterdam University Medical Centres, Academic Medical Centre, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Grootjans</LastName>
            <ForeName>Joep</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0002-2805-4831</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, Amsterdam University Medical Centres, Academic Medical Centre, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>D'Haens</LastName>
            <ForeName>Geert</ForeName>
            <Initials>G</Initials>
            <Identifier Source="ORCID">0000-0003-2784-4046</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology and Hepatology, Amsterdam University Medical Centres, Academic Medical Centre, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>01</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Expert Rev Clin Immunol</MedlineTA>
        <NlmUniqueID>101271248</NlmUniqueID>
        <ISSNLinking>1744-666X</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Etrasimod</Keyword>
        <Keyword MajorTopicYN="N">filgotinib</Keyword>
        <Keyword MajorTopicYN="N">guselkumab</Keyword>
        <Keyword MajorTopicYN="N">inflammatory bowel disease</Keyword>
        <Keyword MajorTopicYN="N">mirikizumab</Keyword>
        <Keyword MajorTopicYN="N">ozanimod</Keyword>
        <Keyword MajorTopicYN="N">ulcerative colitis</Keyword>
        <Keyword MajorTopicYN="N">upadacitinib</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>28</Day>
          <Hour>5</Hour>
          <Minute>6</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35477319</ArticleId>
        <ArticleId IdType="doi">10.1080/1744666X.2022.2069562</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
